Table 5

Mean survival time from first diagnosis to death (or to the end of follow-up time) or to tracheostomy or death (or to the end of follow-up time)

Total (N=3049)*Subgroup (N=714)†
DeathTracheostomy or death‡DeathTracheostomy or death
Mean§SEP values¶Mean§SEP values¶Mean§SEP values¶Mean§SEP values¶
Age
 <4057.71.52<0.000153.41.87<0.000157.42.57<0.000165.43.06<0.0001
 40–4950.81.1946.41.3650.02.1454.52.52
 50–5940.90.8635.30.9137.91.6940.91.95
 ≥6031.40.6427.00.6430.81.2931.51.35
Sex
 Male36.90.600.944631.90.620.678837.01.170.427839.71.330.4384
 Female38.30.8233.70.8437.41.6238.51.72
Income**
 High36.10.790.651531.00.810.121137.41.550.447240.41.770.5236
 Middle37.50.7732.60.8035.61.5237.61.68
 Low39.01.0035.21.0438.81.9440.02.06
Region
 Seoul city††38.81.050.091532.91.090.666141.71.990.088744.22.230.5823
 Metropolitan city‡‡37.81.0330.10.9234.82.0136.42.17
 Other areas§§37.60.6733.50.6937.41.3138.61.39
 Total38.30.5133.50.5238.00.9939.21.05
  • All lengths of time are in months.

  • *Total study subjects (N=3049).

  • †Follow-up more than 5 years from first diagnosis among study subjects (N=714).

  • ‡In total study subjects, there were 25 patients who had an invalid tracheostomy date (underwent tracheostomy before amyotrophic lateral sclerosis diagnosis). When calculating functional end-point survival time in total patients group, we excluded those 25 patients (N=3024).

  • §Mean survival time from first diagnosis to death or to functional end-point (or to the end of follow-up time).

  • ¶P value by log-rank test.

  • **Income-based insurance contributions.

  • ††Seoul metropolitan city.

  • ‡‡Other metropolitan cities.

  • §§Non-metropolitan area.